Education and specialist referral of patients with atopic dermatitis

Green, Robin J.; Pentz, Adele; Jordaan, H.F.

doi:10.7196/samj.8857

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with AD are responsive to dedicated conservative treatment. We recommend referral to a dermatologist in the following indications [ 109 , 110 ]: Same day referral Suspicion of eczema herpeticum—urgent referral, ideally within 1–2 weeks Severe AD irresponsive to optimal topical therapy is seen after 2–4 weeks If treatment of bacterial-infected AD has failed Routine (non-urgent) referral (ideally, every patient shall be seen within 1–4 weeks; however, it might take longer) Diagnosis is uncertain. Partially responded AD to the appropriate treatment and duration.…”

Section: Management Of Atopic Dermatitismentioning

confidence: 99%

National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021)

Fatani

Sheikh

Alajlan

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease with an increasing prevalence regionally and globally. It is characterized by intense itching and recurrent eczematous lesions. With the increase in the availability of treatment options for healthcare practitioner and patients, new challenges arise for treatment selection and approach. The current consensus statement has been developed to provide up-to-date evidence and evidence-based recommendations to guide dermatologists and healthcare professionals managing patients with AD in Saudi Arabia. By an initiative from the Ministry of Health (MOH), a multidisciplinary work group of 11 experts was convened to review and discuss aspects of AD management. Four consensus meetings were held on January 14, February 4, February 25, and March 18 of 2021. All consensus content was voted on by the work group, including diagnostic criteria, AD severity assessment, comorbidities, and therapeutic options for AD. Special consideration for the pediatric population, as well as women during pregnancy and lactation, was also discussed. The present consensus document will be updated as needed to incorporate new data or therapeutic agents.

show abstract

Section: Management Of Atopic Dermatitismentioning

confidence: 99%

National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021)

Fatani

Sheikh

Alajlan

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…This issue of CME consists of six full-length articles, covering the following topics: aetiopathogenesis, [1] epidemiology, [2] diagnosis, [3] patient education and specialist referral, [4] non-pharmacological treatment [5] and pharmacological treatment. [6] Summaries of the general approach to and guideline for the management of AD are also provided (available online only).…”

mentioning

confidence: 99%